Drugs Containing Excipient (Inactive Ingredient) CHONDRUS CRISPUS CARRAGEENAN

« Back to Dashboard

Branded drugs containing CHONDRUS CRISPUS CARRAGEENAN excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aquestive Therapeutics	EXSERVAN	riluzole	10094-350	CHONDRUS CRISPUS CARRAGEENAN

Generic drugs containing CHONDRUS CRISPUS CARRAGEENAN excipient

Company	Ingredient	NDC	Excipient
Aquestive Therapeutics	riluzole	10094-350	CHONDRUS CRISPUS CARRAGEENAN

Chondrus Crispus Carrageenan Market Dynamics, Pharmaceutical Uses, and Financial Trajectory

Last updated: October 5, 2026

Chondrus crispus carrageenan is a specialized seaweed-derived pharmaceutical excipient with applications in oral suspensions, gels, capsules, topical products, and modified-release systems. Its commercial value is driven less by bulk volume than by pharmaceutical-grade documentation, rheology control, microbial limits, traceability, and formulation performance. The market outlook is stable to moderately positive, but growth is constrained by competition from synthetic and plant-based polymers and by the limited public disclosure of species-specific sales.

What is Chondrus crispus carrageenan used for in pharmaceuticals?

Chondrus crispus, commonly known as Irish moss, is a red seaweed historically used to produce carrageenan. Carrageenan is a sulfated galactan polymer that can function as a thickener, suspending agent, gelling agent, stabilizer, film former, and viscosity modifier.

Pharmaceutical uses include:

Function	Typical dosage-form application
Suspending agent	Oral liquids, antacid suspensions, pediatric medicines
Thickener	Syrups, gels, topical preparations
Gelling agent	Oral gels, topical gels, controlled-release matrices
Stabilizer	Emulsions and multiphase formulations
Film former	Coatings and oral delivery systems
Mucoadhesive polymer	Buccal, oral, and topical delivery systems
Capsule or shell component	Soft-gel and vegetarian dosage forms, where formulation compatibility permits

The commercial product is generally sold as carrageenan or by functional type, such as kappa, iota, or lambda carrageenan. Species-specific labeling as “Chondrus crispus carrageenan” is less common than functional or chemical classification. Commercial carrageenan production also uses other red seaweeds, including Kappaphycus and Eucheuma species, which can provide a lower-cost or more scalable supply base (Bixler & Porse, 2011).

How large is the pharmaceutical carrageenan market?

No audited public market series isolates pharmaceutical-grade carrageenan made specifically from Chondrus crispus. Market reports generally combine food, pharmaceutical, personal-care, and industrial carrageenan, then combine all biological sources.

The relevant market should therefore be viewed in three layers:

1. The global carrageenan market, dominated by food applications.
2. The pharmaceutical and healthcare-grade carrageenan segment.
3. The narrow Chondrus crispus-derived pharmaceutical segment.

The third segment is likely a small subset of the second. Its value is supported by higher unit pricing, but volume is limited by formulation-specific demand and substitution.

Market layer	Commercial profile	Financial relevance
Food carrageenan	High-volume, price-sensitive, globally traded	Determines raw-material economics
Pharmaceutical carrageenan	Lower volume, higher qualification and documentation requirements	Produces higher margins per kilogram
Chondrus crispus pharmaceutical carrageenan	Niche, species-specific, traceability-sensitive	Premium positioning but limited scale

Revenue exposure for suppliers is unlikely to be material at the consolidated-company level unless the supplier is a specialized hydrocolloid producer or contract manufacturer. Public companies generally do not report Chondrus crispus carrageenan as a separate business line.

What is the financial trajectory for Chondrus crispus carrageenan?

The financial trajectory is best characterized as low-volume, premium-grade growth rather than mass-market expansion.

Base-case trajectory

The base case is moderate revenue growth supported by:

• Continued demand for oral liquid and topical formulations.
• Expansion of plant-derived and clean-label excipients.
• Increased use of polymers in modified-release and mucoadhesive delivery systems.
• Pharmaceutical manufacturers seeking documented alternatives to gelatin and some synthetic polymers.
• Premium pricing for compendial quality and validated supply.

Growth is limited by the small number of applications that require carrageenan specifically. Most formulations can evaluate substitutes such as hydroxypropyl methylcellulose, sodium alginate, pectin, gellan gum, xanthan gum, carbomer, or polyvinyl alcohol.

Downside case

The principal downside risks are:

• Raw-material supply disruption from seaweed disease, ocean warming, storms, or harvesting restrictions.
• Batch-to-batch variation in molecular weight, sulfation, ash, viscosity, and gel strength.
• Regulatory or consumer concerns regarding carrageenan safety, even where those concerns relate primarily to degraded carrageenan rather than pharmaceutical-grade material.
• Substitution by cellulose ethers, synthetic polymers, or newer delivery technologies.
• Concentration among specialized hydrocolloid producers.
• Price pressure from food-grade or non-compendial alternatives.

Upside case

The upside case depends on carrageenan becoming a preferred polymer in:

• Vegetarian or non-animal-derived capsule systems.
• Mucoadhesive oral delivery.
• Long-acting oral matrices.
• Topical and wound-care formulations.
• Combination hydrocolloid systems with alginate, pectin, or cellulose derivatives.
• Biodegradable delivery platforms.

The strongest commercial opportunity is not bulk carrageenan replacement. It is formulation-specific performance where carrageenan provides a combination of gel strength, ionic responsiveness, viscosity, and consumer acceptance that competing excipients cannot match at the same concentration.

Which companies supply pharmaceutical-grade carrageenan?

Carrageenan production is concentrated among specialized hydrocolloid manufacturers and ingredient companies. Suppliers may offer pharmaceutical, nutraceutical, food, cosmetic, or technical grades under different specifications.

Known industry participants include:

Company or group	Relevant position
CP Kelco	Hydrocolloid producer with carrageenan and related stabilizer capabilities
IFF, including legacy Danisco activities	Global food and specialty hydrocolloid supplier
Gelymar	Carrageenan producer with seaweed sourcing and hydrocolloid processing
CEAMSA	Hydrocolloid and seaweed-derived ingredient supplier
Specialized regional processors	Often provide customized viscosity, mesh size, and formulation grades

The availability of a pharmaceutical grade cannot be inferred from a supplier’s food-grade carrageenan portfolio. Pharmaceutical buyers require documentation covering identity, impurity profile, microbiology, heavy metals, residual solvents where applicable, allergen status, elemental impurities, manufacturing controls, change notification, and supply continuity.

Supplier qualification is therefore a more significant commercial barrier than the basic ability to manufacture carrageenan.

What regulatory status applies to Chondrus crispus carrageenan?

Carrageenan has a long history as a food additive and excipient-like functional material. In the United States, carrageenan is listed in the food-additive regulations under 21 C.F.R. § 172.620. That food authorization does not constitute approval of a particular pharmaceutical product or a blanket approval for every pharmaceutical use.

For drug products, regulatory acceptability depends on:

• The route of administration.
• The amount used.
• The dosage form.
• Prior use in approved drug products.
• The supplier’s quality controls.
• Product-specific safety and compatibility data.

The FDA Inactive Ingredient Database is the principal public reference for prior inactive-ingredient use in approved drug products. An entry supports regulatory precedent but does not eliminate the need for formulation-specific review (U.S. Food and Drug Administration, n.d.-a).

In Europe, carrageenan is recognized as food additive E407. Pharmaceutical use is assessed through the finished product dossier and applicable excipient-quality requirements. The European Medicines Agency expects applicants to address excipient quality, control strategy, safety, and suitability for the intended route and dose (European Medicines Agency, 2016).

What is the Orange Book status of Chondrus crispus carrageenan?

Chondrus crispus carrageenan has no independent Orange Book listing because the FDA Orange Book lists approved drug products, patents, and exclusivity information, not excipients as standalone commercial products (U.S. Food and Drug Administration, n.d.-b).

The relevant regulatory position is:

Issue	Status
Standalone Orange Book product	None
Orange Book patent listing	None for the excipient itself
Drug-product use	Determined at the finished-product level
ANDA relevance	Applicant must identify and justify inactive ingredients
Paragraph IV challenge	Not applicable to carrageenan as an excipient
Biosimilar competition	Not applicable
Excipient exclusivity	None as a standalone category

A generic drug sponsor using carrageenan may still face formulation patents, method-of-use patents, or drug-product patents owned by the reference-product sponsor. Those rights attach to the finished medicine, not to Chondrus crispus carrageenan generally.

What patents protect Chondrus crispus carrageenan?

The underlying natural polymer is not a new pharmaceutical invention. Patent protection is more likely to cover:

• Extraction and purification methods.
• Controlled molecular-weight fractions.
• Crosslinked or chemically modified carrageenan.
• Composite matrices combining carrageenan with another polymer.
• Specific capsule, film, gel, or controlled-release formulations.
• Therapeutic delivery systems using carrageenan.
• Manufacturing controls that produce defined viscosity or gel properties.

Broad claims to naturally occurring carrageenan are vulnerable to novelty and obviousness challenges, particularly where the claims do not define a new composition, process, or use. Commercial differentiation is more likely to arise from trade secrets, specifications, quality systems, validated processes, and customer qualification.

How strong is the patent estate?

The general patent estate is weak for unmodified Chondrus crispus carrageenan and stronger for engineered formulations or delivery systems.

Asset type	Relative protection
Natural Chondrus crispus biomass	Low
Unmodified carrageenan polymer	Low
Defined molecular-weight fraction	Moderate
Purification or extraction process	Moderate
Carrageenan composite formulation	Moderate to strong
Specific drug-delivery system	Potentially strong
Supplier quality specifications	Trade-secret and contractual protection

No standardized patent estate comparable to a branded drug’s composition, formulation, method-of-use, and manufacturing portfolio exists for the excipient itself.

What manufacturing and supply barriers affect the market?

Manufacturing risk begins with the seaweed supply chain. Chondrus crispus is associated with colder-water regions and historically has been harvested from the North Atlantic. Commercial production must manage species authentication, geographic sourcing, seasonal variability, mineral content, microbial contamination, and drying conditions.

The principal barriers are:

1. Consistent raw-material identification.
2. Control of viscosity and gel strength.
3. Removal of sand, salts, proteins, pigments, and other impurities.
4. Control of microbiological and elemental impurities.
5. Demonstrated stability across storage conditions.
6. Reproducible scale-up from laboratory to commercial batch.
7. Regulatory change control and supplier qualification.
8. Reliable dual sourcing.

A pharmaceutical customer may reject a lower-priced supply if switching requires new compatibility studies, stability work, process validation, or regulatory filings. This creates customer stickiness and supports premium pricing after qualification.

What formulation patents and method-of-use patents matter?

Formulation patents are more commercially relevant than species patents. Potentially protected products include:

• Extended-release tablets using carrageenan as a matrix former.
• Oral gels with defined carrageenan concentrations and pH ranges.
• Mucoadhesive films containing carrageenan and a second polymer.
• Topical gels with carrageenan-based rheology control.
• Capsule shells using carrageenan blends.
• Carrageenan-based delivery systems for proteins, peptides, or biologics.

Method-of-use patents may cover administration of a particular drug in a carrageenan-containing dosage form. These rights can restrict generic or follow-on formulation development even when the active ingredient is off patent.

Which companies are challenging carrageenan-based drug products?

There is no meaningful Paragraph IV challenger market for carrageenan as a standalone ingredient. Generic companies challenge approved drug products, not excipients.

Competition occurs through formulation substitution. Drug manufacturers may choose:

• Hydroxypropyl methylcellulose for controlled release.
• Sodium alginate for gel formation and gastrointestinal applications.
• Pectin for oral and nutraceutical systems.
• Gellan gum for low-concentration suspension and gel applications.
• Carbomer for high-viscosity gels.
• Xanthan gum for suspension and rheology control.
• Gelatin or cellulose-based capsule materials.

The competitive threat is therefore formulation-level displacement rather than a direct patent challenge to Chondrus crispus carrageenan.

Are there licensing deals involving Chondrus crispus carrageenan?

Publicly disclosed licensing transactions specifically covering Chondrus crispus pharmaceutical carrageenan are limited. Commercial arrangements are more likely to involve:

• Long-term supply contracts.
• Private-label manufacturing.
• Exclusive geographic distribution.
• Joint development of a finished dosage form.
• Contract extraction or purification.
• Customer-specific specifications.

These arrangements may not appear in public securities filings because the ingredient is usually a small component of a larger specialty-ingredients portfolio.

What litigation affects the market?

No broad, product-class litigation framework comparable to branded pharmaceutical patent litigation applies to Chondrus crispus carrageenan. Potential disputes are more likely to involve:

• Supplier nonconformance.
• Raw-material identity.
• Contamination or batch failure.
• Breach of supply agreements.
• Trade-secret misappropriation.
• Patent disputes over modified carrageenan formulations.
• Regulatory claims concerning product labeling or composition.

Finished-drug litigation may indirectly affect demand if a carrageenan-containing formulation is covered by a listed patent or faces an ANDA challenge. That litigation would concern the drug product and its claims, not the excipient in isolation.

How does Chondrus crispus carrageenan compare with competing excipients?

Excipient	Main advantage	Main limitation
Chondrus crispus carrageenan	Marine-derived gelation, viscosity control, formulation flexibility	Supply variability and limited species-specific scale
HPMC	Strong regulatory familiarity and broad controlled-release use	May require higher use levels or specialized grades
Sodium alginate	Strong gelation and gastrointestinal utility	Ionic sensitivity and batch variability
Pectin	Plant-derived and consumer-friendly	Narrower rheology and gel-control profile
Gellan gum	Efficient suspension and gel performance	More specialized sourcing
Carbomer	Very high viscosity at low concentration	Synthetic origin and pH sensitivity
Xanthan gum	Robust suspension and thickening	Mouthfeel and microbial-control considerations

Chondrus crispus carrageenan is most competitive when a formulation needs marine origin, gel strength, mucoadhesion, or a particular sensory profile. It is less competitive where the buyer prioritizes low cost, broad global availability, or extensive regulatory precedent.

What generic launch risks exist for carrageenan-containing drugs?

Generic launch risk depends on the finished product:

• A simple oral solution with carrageenan as a conventional thickener may have limited formulation differentiation.
• A modified-release product using carrageenan as a critical matrix former may face substantial formulation and patent barriers.
• A topical gel may be vulnerable to design-around using carbomer, HPMC, or alginate.
• A capsule product may face manufacturing and equivalence issues if the excipient affects dissolution or release.
• A biologic or peptide delivery system may face stronger formulation and manufacturing claims.

Carrageenan can support product differentiation, but it rarely provides standalone exclusivity.

Key Takeaways

• Chondrus crispus carrageenan is a niche pharmaceutical excipient, not a separately reported public market category.
• Its commercial value comes from pharmaceutical-grade quality, performance, traceability, and qualification rather than volume.
• Revenue growth is likely to be moderate, with premium pricing offset by substitution and limited species-specific supply.
• The strongest applications are oral suspensions, gels, mucoadhesive systems, topical products, and controlled-release matrices.
• No standalone Orange Book listing, Paragraph IV pathway, biosimilar risk, or excipient exclusivity applies.
• Patent value is concentrated in modified polymers, extraction processes, composite formulations, and drug-delivery systems.
• Supply-chain control and customer qualification are more important competitive barriers than basic composition patents.
• Public financial disclosures do not isolate Chondrus crispus carrageenan revenue, margins, or company-specific exposure.

FAQs

Is Chondrus crispus carrageenan the same as Irish moss?

Yes. Chondrus crispus is commonly called Irish moss. The carrageenan extracted from it is a sulfated seaweed polysaccharide, although commercial carrageenan may also come from other red algae species.

Is carrageenan approved as a pharmaceutical excipient?

Carrageenan has established food-use recognition and prior pharmaceutical use. Acceptance in a drug depends on route, dose, formulation, quality, and regulatory precedent. It is not approved as a standalone drug.

Can carrageenan be used in biologic drug formulations?

It can be evaluated in delivery systems for proteins, peptides, and other biologics, but compatibility, immunogenicity, degradation, sterility, and release performance must be addressed for the specific product.

Does carrageenan create a barrier to generic entry?

Usually not by itself. It can contribute to formulation complexity, dissolution differences, or product-specific patents, but generic manufacturers can often design around it with another polymer.

Is pharmaceutical-grade carrageenan more profitable than food-grade carrageenan?

It can command a higher unit price because of documentation, testing, qualification, and quality controls. Profitability depends on manufacturing scale, raw-material costs, customer concentration, and the cost of maintaining pharmaceutical compliance.

References

1. Bixler, H. J., & Porse, H. (2011). A decade of change in the seaweed hydrocolloids industry. Journal of Applied Phycology, 23(3), 321-335. https://doi.org/10.1007/s10811-010-9529-3

2. European Medicines Agency. (2016). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. European Medicines Agency.

3. Joint FAO/WHO Expert Committee on Food Additives. (2015). Compendium of food additive specifications: Carrageenan. Food and Agriculture Organization of the United Nations and World Health Organization.

4. United States Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientlist

5. United States Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. United States Government Publishing Office. (2024). 21 C.F.R. § 172.620: Carrageenan. Electronic Code of Federal Regulations.

7. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.